- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02927925
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type
December 18, 2020 updated by: Janssen Research & Development, LLC
An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type
The purpose of this study is to assess the clinical efficacy and safety of daratumumab in relapsed or refractory natural killer/T-cell lymphomas (NKTCL).
Study Overview
Study Type
Interventional
Enrollment (Actual)
32
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China, 100142
- Beijing Cancer Hospital
-
Beijing, China, 100021
- Cancer Hospital, Chinese Academy of Medical Sciences
-
Guangzhou, China, 510060
- Sun Yat-sen University Cancer Center
-
Hangzhou, China, 310003
- 1st Affiliated Hospital of Zhejiang University Medical College
-
Shanghai, China, 200025
- Ruijin Hospital, Shanghai Jiao Tong University
-
-
-
-
-
Hong Kong, Hong Kong
- Queen Mary Hospital, University of Hong Kong
-
-
-
-
-
Goyang-si, Korea, Republic of, 10408
- National Cancer Center
-
Seoul, Korea, Republic of, 3080
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 03722
- Severance Hospital
-
Seoul, Korea, Republic of, 5505
- Asan Medical Center
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center
-
Seoul, Korea, Republic of, 06591
- Seoul ST. Mary's Hospital
-
-
-
-
-
Singapore, Singapore, 169608
- Singapore General Hospital
-
Singapore, Singapore, 169610
- National Cancer Centre Singapore
-
-
-
-
-
Changhua, Taiwan, 50006
- Changhua Christian Hospital
-
Taichung, Taiwan, 40447
- China Medical University Hospital
-
Taipei, Taiwan, 10002
- National Taiwan University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Documented as histologically confirmed extranodal natural killer/T-cell lymphomas (NK/T)-cell lymphoma, nasal type according to the World Health Organization (WHO) classification and the pathology report will be verified by the Sponsor
- Failed at least 1 line of chemotherapy and who, according to treating physician or investigator, is not candidate to receive other treatment modalities
- At least 1 measurable site of disease
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2 and life expectancy greater than or equal to (>=) 3 months
Exclusion Criteria:
- Received daratumumab or other antiCD38 therapies previously
- Previous allogenic stem cell transplant or autologous stem cell transplantation within 12 weeks before the first administration of the study drug
- Clinical symptoms of central nervous system involvement
- Known chronic obstructive pulmonary disease, known moderate or severe persistent asthma within the past 2 years, or uncontrolled asthma of any classification
- Clinically significant cardiac disease, including:Myocardial infarction within 6 months before the first study agent administration, or unstable or uncontrolled disease/condition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association Class III-IV); Uncontrolled cardiac arrhythmia (Common Terminology Criteria for Adverse Events [CTCAE] [most recent version] Grade 3 or higher) or clinically significant ECG abnormalities; Screening 12-lead ECG showing a baseline QT interval as corrected QTc >470 msec
- Seropositive for human immunodeficiency virus
- Seropositive for hepatitis B or hepatitis C
- Abnormal laboratory values according to protocol defined parameters at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Daratumumab
Participants will receive daratumumab 16 milligram per kilogram (mg/kg) by intravenous (IV) infusion once weekly for 8 weeks, then every 2 weeks for 16 weeks, then every 4 weeks thereafter until study drug discontinuation due to progressive disease (PD), consent withdrawal or unacceptable toxicity.
|
Participants will receive daratumumab 16 mg/kg as intravenous infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Overall Response
Time Frame: Up to 2 years and 11 months
|
Overall response was defined as the percentage of participants who achieved complete response (CR) or partial response (PR) per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on blinded independent central review (BICR).
As per Revised Response Criteria for Malignant Lymphoma, Lymph node measurements were taken from Computed Tomography (CT), CT portion of the Positron Emission Tomography/Computed Tomography (PET/CT), where applicable.
CR: complete disappearance of all evidence of disease; PR as a greater than (>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
|
Up to 2 years and 11 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Complete Response (CR)
Time Frame: Up to 2 years and 11 months
|
CR was defined as the percentage of participants who achieved CR as per Revised Criteria for Response Assessment of Hodgkin and non-Hodgkin lymphoma: LUGANO classification based on BICR.
CR was a complete disappearance of all evidence of disease.
|
Up to 2 years and 11 months
|
Progression Free Survival (PFS)
Time Frame: Up to 2 years and 11 months
|
PFS was defined as the duration from the date of the first daratumumab dose to the date of progression/relapse or death, whichever came first.
Progressive disease (PD) was defined as any new lesion greater than (>) 1.5 centimeter (cm) in any axis or greater than or equal to (>=) 50 percent (%) increase in previously involved sites.
|
Up to 2 years and 11 months
|
Duration of Response (DoR)
Time Frame: Up to 2 years and 11 months
|
DoR was defined as duration from the date of the initial documentation of a response to the date of first documented evidence of progressive disease (PD) (or relapse for participants who experienced CR).
PD was defined as any new lesion >1.5 cm in any axis or >= 50% increase in previously involved sites.
|
Up to 2 years and 11 months
|
Time to Response
Time Frame: Up to 2 years and 11 months
|
Time to response was defined as the duration from the date of the first dose of daratumumab to the earliest date that a response (CR/PR based on BICR) is first documented.
CR was defined as complete disappearance of all evidence of disease; PR as a greater than (>) 50 percent (%) decrease in the sum of the products of the maximal perpendicular diameters of measured lesions (SPD) and no new sites.
|
Up to 2 years and 11 months
|
Overall Survival (OS)
Time Frame: Up to 2 years and 11 months
|
OS was defined as the duration from the date of the first daratumumab dose to the date of death.
|
Up to 2 years and 11 months
|
Number of Participants With Treatment Emergent Adverse Events (TEAE) as a Measure of Safety and Tolerability
Time Frame: Up to 2 years and 11 months
|
An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
TEAE were defined as AEs with onset during the treatment period or that are a consequence of a pre-existing condition that has worsened since baseline.
|
Up to 2 years and 11 months
|
Number of Participants With Clinically Significant Change in Vital Signs
Time Frame: Up to 2 years and 11 months
|
Number of participants with clinically significant change in vital signs (blood pressure, temperature, pulse rate, and weight) was reported.
|
Up to 2 years and 11 months
|
Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities
Time Frame: Up to 2 years and 11 months
|
Number of participants with clinically significant ECG abnormalities were reported.
|
Up to 2 years and 11 months
|
Number of Participants With Clinically Significant Change in Physical Finding
Time Frame: Up to 2 years and 11 months
|
Number of participants with clinically significant change in physical finding was reported.
|
Up to 2 years and 11 months
|
Number of Participants With Clinically Significant Change in Laboratory Parameters
Time Frame: Up to 2 years and 11 months
|
Number of participants with clinically significant change in hematology (WBC, hemoglobin, platelets, neutrophils, and lymphocytes) and biochemistry (alanine transaminase [ALT], aspartate transaminase [AST], sodium, potassium, bilirubin, alkaline phosphatase, calcium laboratory parameters were reported.
|
Up to 2 years and 11 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 14, 2017
Primary Completion (Actual)
January 2, 2020
Study Completion (Actual)
January 7, 2020
Study Registration Dates
First Submitted
October 6, 2016
First Submitted That Met QC Criteria
October 6, 2016
First Posted (Estimate)
October 7, 2016
Study Record Updates
Last Update Posted (Actual)
January 14, 2021
Last Update Submitted That Met QC Criteria
December 18, 2020
Last Verified
December 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR108237
- 54767414NKT2001 (Other Identifier: Janssen Research & Development, LLC)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditionsUnited States, Canada, Australia, Puerto Rico
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedFollicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell LymphomaUnited States
-
Novartis PharmaceuticalsCompletedDiffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaUnited States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Clinical Trials on Daratumumab
-
Janssen Research & Development, LLCActive, not recruitingSmoldering Multiple MyelomaUnited States, Netherlands, Belgium, Canada, Israel, Czechia, Denmark, Japan, Hungary, Turkey, United Kingdom, Spain, Sweden, France, Germany, Italy, Russian Federation, Poland, Mexico, Australia, Brazil, Greece, Argentina, Norway
-
Boston Medical CenterJanssen PharmaceuticalsCompleted
-
National Cancer Institute (NCI)RecruitingLymphoma, Primary EffusionUnited States
-
University of ArkansasJanssen Scientific Affairs, LLCRecruiting
-
Incyte CorporationTerminatedRelapsed or Refractory Multiple MyelomaUnited States, Spain, Germany
-
Ostfold Hospital TrustOdense University Hospital; Oslo University Hospital; Haukeland University Hospital and other collaboratorsActive, not recruiting
-
Ronald WittelesCompletedHeart Transplant Failure and Rejection | AllosensitizationUnited States
-
Charite University, Berlin, GermanyJanssen-Cilag G.m.b.H; Labor Berlin-Charité Vivantes G.m.b.H; Deutsches Rheuma-Forschungszentrum... and other collaboratorsNot yet recruiting
-
Marc L Gordon, MDJanssen Scientific Affairs, LLCCompletedAlzheimer DiseaseUnited States
-
Hoffmann-La RocheCompletedMultiple MyelomaUnited States, Australia, United Kingdom